Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

Katrine Finderup Nielsen; Lise Birk Nielsen; Tine Dalby; Frederikke Kristensen Lomholt; Hans-Christian Slotved; Kurt Fuursted; Zitta Barrella Harboe; Charlotte Sværke Jørgensen; Palle Valentiner-Branth

doi:10.3201/eid3006.230975

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

Katrine Finderup Nielsen^*, Lise Birk Nielsen, Tine Dalby, Frederikke Kristensen Lomholt, Hans-Christian Slotved, Kurt Fuursted, Zitta Barrella Harboe, Charlotte Sværke Jørgensen, Palle Valentiner-Branth

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

4 Citationer (Scopus)

7 Downloads (Pure)

Abstract

As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020–January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.

Originalsprog	Engelsk
Tidsskrift	Emerging Infectious Diseases
Vol/bind	30
Udgave nummer	6
Sider (fra-til)	1164-1172
Antal sider	9
ISSN	1080-6040
DOI	https://doi.org/10.3201/eid3006.230975
Status	Udgivet - 2024

Bibliografisk note

Funding Information:
H.C.S. reports involvement with MSD seminars and is part of a Pfizer supported pneumococcal carriage project. Z.B.H. received a grant from Independent Research Fund (grant no. 0134-00257B), Lundbeck Foundation (grant no. R349-2020-835), Helen Rudes Foundation, and the Danish Cancer Society (grant no. KBVU-MS R327-A19137).

Publisher Copyright:
© 2024 Centers for Disease Control and Prevention (CDC). All rights reserved.

Adgang til dokumentet

10.3201/eid3006.230975Licens: CC BY

FulltextForlagets udgivne version, 1,3 MBLicens: CC BY

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Nielsen, K. F., Nielsen, L. B., Dalby, T., Lomholt, F. K., Slotved, H.-C., Fuursted, K., Harboe, Z. B., Jørgensen, C. S., & Valentiner-Branth, P. (2024). Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark. Emerging Infectious Diseases, 30(6), 1164-1172. https://doi.org/10.3201/eid3006.230975

Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark. / Nielsen, Katrine Finderup; Nielsen, Lise Birk; Dalby, Tine et al.
I: Emerging Infectious Diseases, Bind 30, Nr. 6, 2024, s. 1164-1172.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Nielsen, KF, Nielsen, LB, Dalby, T, Lomholt, FK, Slotved, H-C, Fuursted, K, Harboe, ZB, Jørgensen, CS & Valentiner-Branth, P 2024, 'Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark', Emerging Infectious Diseases, bind 30, nr. 6, s. 1164-1172. https://doi.org/10.3201/eid3006.230975

@article{065991e7e734454891266b3f7da8d272,

title = "Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark",

abstract = "As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020–January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.",

author = "Nielsen, {Katrine Finderup} and Nielsen, {Lise Birk} and Tine Dalby and Lomholt, {Frederikke Kristensen} and Hans-Christian Slotved and Kurt Fuursted and Harboe, {Zitta Barrella} and J{\o}rgensen, {Charlotte Sv{\ae}rke} and Palle Valentiner-Branth",

year = "2024",

doi = "10.3201/eid3006.230975",

language = "English",

volume = "30",

pages = "1164--1172",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "U.S. Department of Health and Human Services Centers for Disease Control and Prevention",

number = "6",

}

TY - JOUR

T1 - Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark

AU - Nielsen, Katrine Finderup

AU - Nielsen, Lise Birk

AU - Dalby, Tine

AU - Lomholt, Frederikke Kristensen

AU - Slotved, Hans-Christian

AU - Fuursted, Kurt

AU - Harboe, Zitta Barrella

AU - Jørgensen, Charlotte Sværke

AU - Valentiner-Branth, Palle

PY - 2024

Y1 - 2024

N2 - As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020–January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.

AB - As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020–January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.

U2 - 10.3201/eid3006.230975

DO - 10.3201/eid3006.230975

M3 - Journal article

C2 - 38781925

AN - SCOPUS:85194125959

SN - 1080-6040

VL - 30

SP - 1164

EP - 1172

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 6

ER -